BACKGROUND: Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, following the publication of a meta-analysis that suggested a 43% increase in the risk of myocardial infarction with the use of rosiglitazone. This alert was followed by a black box warning on August 14, 2007, that was updated 3 months later. While large declines have been documented in rosiglitazone use in clinical practice, little is known about how the use of rosiglitazone and other glucose-lowering drugs varied within the Department of Veterans Affairs (VA), surrounding the FDA alerts. Understanding this variation within integrated health care systems is essential to formulating policies that enhance patient protection and quality of care.
METHODS:
We conducted a retrospective analysis of drug use patterns for all major diabetes drugs in a national cohort of 550,550 veterans with diabetes from 2003 to 2008. This included the time periods when rosiglitazone was added to (November 2003) and removed from (October 2007) the VA national formulary (VANF). We employed multivariable logistic regression models to statistically estimate the association between a patient's location and the patient's odds of using rosiglitazone.
RESULTS: Aggregate rosiglitazone use increased monotonically from 7.7%, in the quarter it was added to the VANF (November 4, 2003) , to a peak of 15.3% in the quarter when the FDA issued the safety alert. Rosiglitazone use decreased sharply afterwards, reaching 3.4% by the end of the study period (September 30, 2008) . The use of pioglitazone, another glucoselowering drug in the same class as rosiglitazone, was low when the FDA issued the safety alert (0.4%) but increased sharply afterwards, reaching 3.6% by the end of the study period. Insulin use increased monotonically; metformin use remained relatively flat; and sulfonylurea use exhibited a general declining trend throughout the study period. Statistically significant geographic variation was observed in rosiglitazone use throughout the study period. The prevalence range, defined as the range of minimum to maximum use across VISNs was 3.7%-12.4% in the first quarter (January 1 to March 31, 2003); 1.0%-5.5% in the last quarter of study period (July 1 to September 30, 2008); and reached a peak of 9.6%-25.5% in the quarter when the FDA safety alert was issued (April 1 to March 31, 2007). In 5 VISNs, peak rosiglitazone use occurred before the FDA issued the safety alert. The odds ratio of using rosiglitazone in a given VISN varied from 0.55 (95% CI = 0.52-0.59; VISN 10) to 1.58 (95% CI = 1.50-1.66; VISN 15), with VISN 1 being the reference region. The variation was higher in the periods after the FDA issued the safety alert. Much less variation was observed in the use of pioglitazone, metformin, sulfonylurea, and insulin.
R E S E A R C H
C linicians face a constant challenge of deciding whether to prescribe newly available medications and when to stop medications based on newly discovered adverse drug effects, particularly when the U.S. Food and Drug Administration (FDA) issues warnings. 1, 2 This challenge is heightened for drugs with FDA "boxed" warnings, its strongest labeling requirements for high-risk medicines. 1 Previous research has shown that clinician response to FDA warnings 
What is already known about this subject
• This is the first study to document geographic variation in rosiglitazone use within the VA before and after the FDA safety alert.
• Statistically significant regional variation was found in rosiglitazone use throughout the study period, including the time periods when rosiglitazone was added into, and removed from, the VA national formulary. Much less variation was observed in the use of other glucose-lowering drugs.
• Rosiglitazone use decreased sharply following the FDA safety alert (78% in 15 months). During the same period, insulin and pioglitazone use increased, while metformin and sulfonylurea use decreased.
the VANF on October 4, 2007, and recommended, through its newsletter, that clinicians discuss the risks and benefits of continued rosiglitazone use with their patients. We evaluated the use of rosiglitazone and other major glucose-lowering drugs within the VA and documented the geographic differences throughout our study period. We statistically estimated the effect that a patient's VISN had on the odds of using rosiglitazone. To our knowledge, this is the first study that identifies geographic variation in rosiglitazone use in the VA and covers 3 key events: rosiglitazone's addition to the VANF, the FDA safety alert for rosiglitazone, and rosiglitazone's removal from the VANF.
■■ Methods Data
We constructed a longitudinal dataset over a 6-year period that included the 3 key events already mentioned. Our study cohort consisted of patients from across the 21 VISNs, who were aged 40 years or older on October 1, 2002, and had diabetes. Patients were included if they met 1 of the following 2 criteria: (1) 21 Since glucose monitoring is an essential part of diabetes management, our cohort included only those patients for whom hemoglobin A1c (A1c) values were available at baseline. Further, we excluded patients with missing values of enrollment priority, date of death, and patient identifiers, resulting in 550,550 unique patients (Figure 1 ). We aggregated health care data of all included patients on a quarterly basis, which resulted in 9,829,507 unique patient-quarter observations. A quarter was defined according to a calendar year (e.g. 
Variables
The main outcome variable of interest was a binary indicator of whether a veteran was using rosiglitazone. The key predictor variable was the patient's VISN, determined by where the veteran's primary care provider was located. The current VISN structure was established in March 1995 with a goal to decentralize decision making and provide greater consistency in the quality of care systemwide. 22 Appendix A (available in online article) lists all the VISNs, including the larger geographic region in which each VISN is located; we adopted the definition of region from Egede et al. (2011) . 23 may be inadequate, which has the potential to jeopardize patient health. 1, 3 Additionally, there may be geographic variation in clinician response to the FDA warnings, implying that patients' locations may determine their extent of exposure to the potential risk of adverse drug events. Understanding this variation is critical to policymakers and health system administrators responsible for communicating guidelines for drug use to their clinicians, particularly in integrated health care systems, where the nature and extent of the observed variation may influence their actions.
One of the landmark examples of a boxed FDA warning is that for the glucose-lowering drug rosiglitazone. On May 21, 2007, the FDA issued a safety alert on rosiglitazone, 4 following the publication of a meta-analysis that suggested a 43% increase in the risk of myocardial infarction with rosiglitazone. 5 On August 14, 2007, the FDA issued a boxed warning for the drug that was updated 3 months later. 6, 7 As a result of these warnings, large declines in rosiglitazone prescriptions were observed in clinical practice in the United States. 3, [8] [9] [10] [11] [12] [13] [14] [15] A large body of research, led by The Dartmouth Atlas of Health Care, has documented significant geographic variation in the cost, quantity, and quality of health care in the United States. 16 Within the Department of Veterans Affairs (VA), the largest integrated health care system in the United States, studies have documented significant geographic variation in various aspects of patient care and outcomes. [17] [18] [19] However, there is relatively limited literature documenting geographic variation in drug use in an integrated health care system such as the VA. One study by Shah et al. (2010) documented significant geographic variation in rosiglitazone prescriptions in a non-VA setting. 3 To better understand the geographic variation in rosiglitazone use, we conducted a retrospective analysis of a national cohort of veterans over a 6-year period. The VA is divided into 21 regions, called the Veterans Integrated Service Networks (VISNs). VISNs provide integrated care to veterans based on geographic location and differ by regional leadership and policies, thus providing a useful setting to investigate geographic variation.
The VA can influence the prescribing behavior of its clinicians by adding or removing drugs from its national formulary (VANF); the formulary composition is the same across all VISNs. To prescribe a nonformulary drug, a physician must first make a request, which is reviewed by a pharmacist. If the request is approved, the drug is provided to the patient as part of normal VA care and does not affect patient benefits. 20 Rosiglitazone was added to the VANF on November 4, 2003. The VA communicated the FDA alert for rosiglitazone internally on May 21, 2007, the same day it was issued. After an internal investigation, the VA removed rosiglitazone from Covariates and potential risk factors included patient demographics at baseline: age, gender, race, marital status, and enrollment priority. Additionally, we included Charlson Comorbidity Index scores at baseline, as defined by Deyo et al. (1992) , 24 and the patient's duration of diabetes. Other covariates included the patients' use of other glucose-lowering drugs, their lab results, and whether they experienced any diabetes-related clinical events, including cardiovascular complications, microvascular complications, and hypoglycemia, in the same time period.
The glucose-lowering medications were classified as either injectable (insulin) or oral (metformin, sulfonylurea, pioglitazone, and rosiglitazone). Pioglitazone, belonging to the same thiazolidinedione class of medications as rosiglitazone, was never on the VANF. Metformin, sulfonylurea, and insulin were on the VANF through the entire study period. A patient was considered to be using a drug if the patient possessed at least a 30-day supply of the drug in a given quarter, irrespective of the dosage. The 30-day supply threshold also served as a proxy for medication adherence. Drug use was measured as the percentage of total patients in that VISN and/or time period. All numbers represent the usage at the end of each quarter.
Laboratory results were continuous, time-varying variables and included glucose levels (A1c); triglycerides and cholesterol (high-density lipoprotein, low-density lipoprotein, total); blood pressure (systolic and diastolic); and body mass index. We implemented the "last observation carried forward" method to populate the missing laboratory values and created clinically relevant categorical variables (see Appendix B for ranges and categories, available in online article). 25 When multiple values were observed for a given measure in a quarter, we averaged those values.
At the organizational level, we included the facility where the patient's primary care provider was located (719 total) and the facility's parent station (128 total). Facility-level covariates included the number of operating beds and indicators for the following: affiliation with a teaching hospital, urban location, and whether it was a community-based outpatient clinic.
Statistical Analysis
We summarized the baseline characteristics of our cohort, at the VISN and the aggregate VA level, as means ± standard deviation (SD) and/or percentage of patients. We compared patients' demographic and clinical characteristics as well as overall facility characteristics between the 21 VISNs using analysis of variance. We compared drug use across time periods using a generalized linear model, where we included the first 3 quarters of the calendar year 2003 (2003 Q1-2003 Q3) to show how rosiglitazone's addition to the VANF affected the usage patterns of all glucose-lowering drugs.
We used the following measures to capture variation in the use of drugs: (a) variation factor: ratio of maximum to minimum use across all the VISNs and (b) range: difference between maximum and minimum use across all the VISNs. We employed a fixed-effects multivariate logistic regression model to statistically estimate the association between patients' location (VISN) and their likelihood of using rosiglitazone, expressed as odds ratio (OR). We conducted this regression analysis for 3 separate time periods: the entire study period (20 quarters), prewarning periods (14 quarters), and postwarning periods (the last 6 quarters). All statistical tests used a two-tailed α = 0.05 level of Only outpatients with documented diagnosis for diabetes n = 859,454
Only patients aged 40-99 years with at least 1 quarter of data in the observation period n = 825,398
Excluded patients with missing A1c values at baseline n = 648,262
Excluded patients with inconsistencies in "new user" coding, date of death, and enrollment priority n = 573,263
Excluded patients with missing facility data, missing lab data, and inconsistency in date of death significance. All standard errors were robust and corrected for clustering at the patient level. All statistical analyses were conducted using Stata version 12 (StataCorp, College Station, TX) and SAS version 9.3 (SAS Institute, Cary, NC).
■■ Results Baseline Characteristics
We observed statistically significant differences in patient demographic and clinical characteristics between the VISNs ( Table 1 ). The average age of the cohort was 66.9 years, ranging from 64.9 years (VISN 17) to 69. using the drugs, respectively. Thirty percent of our cohort belonged to the VISNs in the South region. On average, the annual mortality rate of our cohort was 5.2%, consistent with previous literature. Figure 2 shows the usage patterns for various diabetes drugs at the aggregate national level. Unless otherwise noted, P < 0.0001. 
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Patterns of Medication Usage: Temporal Trend
Patterns of Medication Usage: Geographic Variation
There were differences in rosiglitazone use between the VISNs throughout the study period (Table 2 and The use of pioglitazone, which was never on the VANF, remained low throughout the observation period. After an initial increase (from 2.3% to 2.9% in the first 3 quarters), pioglitazone use started to decrease, reaching 0.4% in 2007 Q2. However, in the time periods following rosiglitazone's removal from the VANF, pioglitazone use increased rapidly, reaching 3.6% by the end of the study period.
The use of other 3 drugs (metformin, sulfonylurea, and insulin) increased for the first 3 quarters until rosiglitazone was added to the VANF (2007 Q2). However, the trend was different in the following periods. Metformin use remained relatively stable, increasing by 1.2% during the time when Some variation was observed in pioglitazone use, particularly during the periods when rosiglitazone was not in the VANF; however, the results should be tempered by the fact that, in absolute terms, pioglitazone use remained relatively low, except for VISN 17, a region where we observed the following interesting features. First, pioglitazone use in VISN 17 was very high until 2005 Q4; for example, in 2005 Q2, pioglitazone use was almost 8 times the maximum use across the rest of the VISNs. Second, the timing of the decline in pioglitazone use coincided with that of the rise in rosiglitazone use. Finally, total thiazolidinedione use was the highest in VISN 17 before the FDA issued the safety alert. Metformin, sulfonylurea, and insulin use exhibited relatively less variation. Table 2 lists the use of various drugs, expressed in terms of quartiles: maximum, first (25th percentile), second (median), third (75th percentile), minimum. Appendix D (available in online article) visually depicts the pattern of drug use by each VISN.
Estimating the Region Effect
We found statistically significant geographic variation in rosiglitazone use after controlling for all observable covariates (Table 3 and Appendix E, available in online article). With VISN 1 serving as the reference region, the odds ratio For sensitivity analysis, we changed the threshold level of days supply employed for classifying whether a patient is a user of the drug from 30 days to 45 days and 60 days. The regression results for the entire observation period (Appendix G, available in online article) reveal that ORs did not change in any meaningful way, regardless of which threshold level was used. In addition, we conducted an analysis where we used a 30-day equivalent as an alternate measure of drug use. This means that instead of drug use being a binary variable, it was a categorical variable with 4 values, -0, 1, 2, and 3, depending on whether the days supply for a drug was 0 days, 1-29 days, 30-59 days, or greater than 60 days, respectively, in a given quarter. 27 In general, we observed similar results in terms of the absolute values as well as ordering of VISNs based on ORs (Appendix H, available in online article). factor = 2.7). The variation factor increased rapidly afterwards, reaching 5.4 by the end of the study period. In contrast, the range of rosiglitazone use remained steady until 2005 Q2, when it was 9.6%, increased afterwards to a peak of 16%, but decreased to 4.5% in the end.
There were geographic differences in the timing of peak use in each VISN. 
Geographic Variation in the Use of Various Glucose-Lowering Drugs
■■ Discussion
Aggregate rosiglitazone use in the VA declined by 78% in the 15 months following the FDA safety alert for the drug, indicating a swift response by the VA clinicians and highlighting the potential strength of the mechanisms through which the VA communicates FDA warnings to its clinicians. This response is similar to previously published studies in a non-VA setting, most notably to that of Shah et al., who reported a 75% decline in monthly rosiglitazone prescriptions dispensed in 30 months following the FDA alert. 3 The increase in pioglitazone and insulin use following the FDA alert suggests that the VA clinicians used them as alternatives to rosiglitazone.
We found considerable geographic variation in rosiglitazone use throughout the study period. The two-fold increase in the variation factor from 2007 Q2 to 2008 Q3 is higher than what an earlier study of non-VA data reported and more than what was observed for metformin, sulfonylureas, and insulin. 3 Further, this variation persisted after controlling for patientand facility-level covariates that may be associated with rosiglitazone prescriptions. Our regression analysis revealed that the patient's VISN significantly, and differentially, affected the odds of using rosiglitazone. While the geographic variation, in terms of the variation factor and odds ratio, increased after the FDA warnings, our conclusions should be tempered by the fact that the range, as well as the actual rosiglitazone use, decreased substantially after the FDA warnings.
In the United States, where large geographic differences in incidence of diabetes, glycemic control, and medication adherence exist, geographic variation in drug use may not be surprising. 23, [28] [29] [30] This variation has been attributed to clinicians' practice styles and how they translate FDA warnings into practice. 3, 11 Within the VA, we expected less variation in drug use given that the VA has a closed pharmacy and a national 
Odds Ratios (95% CIs) Representing the Odds of a Veteran with Type 2 Diabetes Receiving a Rosiglitazone Prescription
formulary used across all VISNs, a relatively homogeneous population with well-established eligibility criteria for veterans and a physician workforce that is salaried with financial incentives that are unaffected by practice patterns. Moreover, many administrative policies are uniform across all VISNs, and adherence to clinical guidelines and VA policy are frequently used as facility performance indicators.
We believe that some of the variation may be explained by local practice patterns that spill over to the VA, since (a) many VA clinicians practice outside of the VA (e.g., those affiliated with teaching hospitals) and may behave similar to non-VA clinicians, 17,31 and (b) veterans who receive the initial prescription from the non-VA clinicians may get it subsequently refilled from a VA clinician. 31 For rosiglitazone, which exhibited a persistently high variation, more than that of other drugs, there may be other contributing factors. First, some physicians may have continued to prescribe rosiglitazone to their patients for whom they thought the benefits outweighed the added potential risk. Moreover, since the decision to discontinue rosiglitazone may come from either the patient or the physician, 32 patients may have decided to discontinue rosiglitazone at different times. It must be noted that the boxed warning did not explicitly prohibit the use of rosiglitazone. Second, the increased role of the pharmacist has been linked to better prescribing behavior of doctors. 33, 34 In this instance, pharmacists may have been better integrated to clinical practice in some VISNs than in others, which may have led to some variation. Finally, many patients, particularly those with stable diabetes and/or those living in rural areas, may visit their clinicians infrequently (e.g., twice a year) and have their medications mailed to them for use between visits, leading to the variation in when they stopped using rosiglitazone. We note that the fraction of people living in rural areas ranged from 0.1% (VISN 1) to 30.9% (VISN 6).
Our analysis reveals other interesting patterns. In 5 VISNs, peak rosiglitazone use occurred before the FDA issued the safety alert, suggesting that some clinicians may have learned about the harmful effects of rosiglitazone earlier than others. For example, VISN 11, where rosiglitazone use started to decline the earliest, is also the location of the VA Diabetes Quality Enhancement Research Initiative, whose mission is to conduct translational research to improve diabetes care. 35 Presumably, geographic proximity to information sources allows clinicians to have quicker access to relevant information. 3, 36 Finally, VISN 10, where the likelihood of rosiglitazone use was the lowest, is home to Cleveland Clinic, the affiliation of the authors of the 2007 study that linked rosiglitazone to an increased myocardial infarction risk.
5
Limitations
Our study has several limitations. First, our data were restricted to the VA and did not include prescriptions or services that patients may have obtained from outside of the VA. The cost of medications is lower in the VA than in the private sector. Therefore, it is quite likely that most veterans obtained their diabetes medications from the VA; consequently, we estimate the effect of omitting non-VA data to be relatively small. Further, the overwhelming majority of our cohort was male (98.2%) and non-Hispanic white (71.2%). While this may not be fully representative of the true composition of diabetes patients, we believe that the policy implications from our results are still valid. Second, we aggregated our data into quarters, which prevented us from analyzing trends at a more granular level. Third, our findings may have been impacted by the rules we used to identify whether a patient is using a medication. As previously discussed, our sensitivity analyses on different rules show this effect to be minimal. Fourth, patients whose primary care facilities were located in rural locations may have lacked access to appropriate and evidence-based medical care, contributing to the observed geographic variation. However, our results do not change in any meaningful way when we limit the data to patients whose primary care facilities were in urban locations (Appendix I, available in online article). Fifth, we did not compare active versus passive dissemination of FDA advisories, which may evoke a different clinician response; we leave this for future study. Finally, we did not explore or analyze causes of variation, for example, why pioglitazone (rosiglitazone) was high (low) in VISN 17. We also leave this as future work.
■■ Conclusions
In examining the largest health care system in the United States, our study strengthens the argument that local practice patterns of care affect how clinicians learn and translate the FDA warnings into practice, given the significant geographic variation observed. From a policy perspective, our study highlights the need for mechanisms to disseminate information and guidelines for drug use in a consistent and reliable manner and ensure a systemwide clinical adherence to FDA warnings noted to be of utmost importance for patient safety. 37 Finally, our study reveals opportunities for learning from high-performing divisions of the system to increase the overall efficiency. This has the potential to reduce the geographic variation in clinician response and ultimately improve the timeliness and quality of patient care.
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